

\$ IMPROVEMENT TO YOUR BOTTOM LINE



Mannheimia haemolytica is the primary cause of bacterial pneumonia and the No. 1 calf killer.¹² Bovine viral diarrhea (BVD) Types 1 and 2 viruses are two of the major viral causes of bovine respiratory disease (BRD).

ONE SHOT[®] BVD helps provide protection against all three.

M. haemolytica + BVD TYPE 1 + BVD TYPE 2

For healthier, higher-value calves on sale day, help protect calves from BRD at a young age. In one convenient dose, ONE SHOT BVD offers the same level of protection as ONE SHOT and BOVI-SHIELD GOLD[®] BVD administered independently.

COMPLETE RESPIRATORY PROTECTION FOR CALVES.

Use ONE SHOT[®] BVD and INFORCE 3[®] concurrently for protection to help get calves started off right in the backgrounder, stocker or feed yard.



USE CONCURRENTLY ON ARRIVAL FOR BACKGROUNDERS, STOCKERS OR FEEDLOTS.

INFORCE 3[®]

- A single intranasal dose rapidly provides protection where viruses attack first.
- Provides at least six months of protection against IBR respiratory disease after single nostril administration.
- The first and only respiratory vaccine labeled for the prevention of disease caused by BRSV.

Convenient, comprehensive protection from:


- Bovine respiratory syncytial virus (BRSV)
- Infectious bovine rhinotracheitis (IBR) virus
- Parainfluenza 3 (Pl3) virus
- M. haemolytica
- BVD Types 1 and 2 viruses

And the distribution of th

- The highest level of protection available against *M. haemolytica* and BVD Types 1 and 2 viruses.
- Helps neutralize *M. haemolytica* leukotoxins before they can destroy white blood cells and lead to lung damage.
- Rapid protection against *M.* haemolytica and BVD respiratory disease.³

INFORCE 3° + ONE SHOT° BVD DEMONSTRATED \$ PER HEAD ADVANTAGES

TRIAL RESULTS DEMONSTRATED DIFFERENCES IN VACCINE PROTOCOLS.



USE INFORCE 3 + ONE SHOT BVD FOR CATTLE ON ARRIVAL

HEALTH AND PERFORMANCE RESULTS DURING 60-DAY RECEIVING PERIOD

	Treatment			
ltem	Group A (Inforce 3 + One Shot BVD; Bovi-Shield GOLD 5)	Group B (Pyramid 5 + Presponse SQ Pyramid 5)	Group C (Vista Once SQ; Vista 5 SQ)	P value
Pens	16	16	16	
Initial head count (n)	483	481	478	
1st BRD treatment (%)	42.7	44.1	46.6	0.49
2nd BRD treatment (%)	8.0ª	10.1 ^{ab}	13.6 ^b	0.01
3rd BRD treatment (%)	3.7ª	3.7ª	6.7 ^b	0.03
Mortality (%)	4.4	6.4	7.6	0.09
Chronics (%)	1.7	0.9	1.5	0.55
Initial body weight (lb)	477.0	477.0	474.0	0.84
Day 60 body weight (lb)	617.0	615.0	615.0	0.94
Deads-in Performance				
Avg. daily gain (lb)	2.2	2.1	2.1	0.69
Avg. daily DM intake (lb)	12.8	13.0	13.0	0.83
Feed/Gain*	5.8	6.1	5.9	0.27
Deads-out Performance				
Avg. Daily Gain (lb)	2.3	2.3	2.4	0.62
Feed/Gain*	5.5	5.2	5.2	0.46

^{ab}Least squares means in rows with different superscripts are significantly different ($p \le 0.05$) *Feed to gain was analyzed as separate variables, not simply a ratio of ADG and DMI shown above.

TALK TO YOUR ZOETIS REPRESENTATIVE OR VETERINARIAN ABOUT INFORCE 3 AND ONE SHOT BVD.

INFORCE 3 + ONE SHOT

Or visit completecalfprotection.com.

U.S. Department of Agriculture. Animal and Plant Health Inspection Service. Mortality of calves and cattle on U.S. beef cow-calf operations. Available at: http://www.aphis.usda.gov/animal_health/nahms/beefcowcalf/downloads/beef0708/beef0708_is_Mortality.pdf. Accessed February 10, 2019. 'Powell J. Livestock Health Series: Bovine Respiratory Disease. University of Arkansas Cooperative Extension Service. FSA 3082. 2009. 'Data on file, Walz PH, Riddle KP, Richardson AP, et al. Impact of passive immunity induced by maternal vaccination on subsequent immunization and disease-sparing in early-weaned beef calves challenged with highly virulent BVDV, Zoetis Inc.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. Pyramid and Presponse are registered trademarks of Boehringer Ingelheim Vetmedica, Inc. Vista is a registered trademark of Merck, Inc. © 2019 Zoetis Services LLC. All rights reserved. INF-00077



BVD